Aprea Therapeutics (NASDAQ: APRE) CEO receives new equity awards
Rhea-AI Filing Summary
Aprea Therapeutics president and CEO Gilad Oren reported new equity awards. He received stock options for 80,700 shares of common stock at an exercise price of $0.765 per share, expiring on March 12, 2036. These options vest 25% on March 12, 2027, with the remainder vesting ratably over the following 36 months, subject to continued employment.
Oren was also granted 20,175 restricted stock units that vest in three equal annual installments beginning on March 12, 2027, also subject to continued employment. Following these grants, he directly holds 393,895 shares of common stock. Additional indirect holdings of 1,200 and 600 shares are reported for his daughter and son, with beneficial ownership disclaimed.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 20,175 shares
Net Buy
4 txns
Insider
Gilad Oren
Role
President/CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to Buy) | 80,700 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 20,175 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Options (Right to Buy) — 80,700 shares (Direct);
Common Stock — 393,895 shares (Direct);
Common Stock — 1,200 shares (Indirect, By Daughter);
Common Stock — 600 shares (Indirect, By Son)
Footnotes (3)
- F1. These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 12, 2027, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
- F2. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- F3. Twenty-five percent of these options vest on March 12, 2027, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Aprea Therapeutics (APRE) disclose in Gilad Oren’s latest Form 4?
Aprea Therapeutics reported that CEO Gilad Oren received new equity awards, including stock options and restricted stock units. These are compensation-related grants, not open-market purchases, and they increase his reported direct and indirect exposure to Aprea common stock over time.
How many stock options were granted to Aprea Therapeutics CEO Gilad Oren?
Gilad Oren received stock options covering 80,700 shares of Aprea common stock at an exercise price of $0.765 per share. The options expire on March 12, 2036 and vest over four years, starting on March 12, 2027, subject to his continued employment.
What restricted stock units (RSUs) did Gilad Oren receive from Aprea Therapeutics (APRE)?
Gilad Oren was granted 20,175 restricted stock units that will settle in Aprea common stock. These RSUs vest in three equal annual installments beginning on March 12, 2027, assuming he remains employed through each vesting date or qualifies for any applicable acceleration conditions.
Are Gilad Oren’s Aprea Therapeutics equity awards open-market stock purchases?
No, the reported transactions are compensation-related grants, not open-market purchases. The Form 4 uses code “A” for grant or award acquisitions, covering stock options and restricted stock units that vest over time rather than immediate market transactions for cash consideration.
What are the vesting conditions for Gilad Oren’s new Aprea Therapeutics equity awards?
The RSUs vest in three equal annual installments starting on March 12, 2027, while 25% of the options vest that same date and the rest over 36 months. Both awards require his continued employment and may accelerate only under specified conditions described in the footnotes.